CoronavirusCovid-19Health

Moderna to Begin COVID-19 Vaccine Trials in Children

Moderna will soon begin coronavirus vaccine trials in babies and children.

The drugmaker’s study, called KidCOVE, will test the vaccine in children ages six months to 11 years old, with the hope of enrolling 6,750 children in the U.S. and Canada, the company announced Tuesday.

“We are pleased to begin this Phase 2/3 study of mRNA-1273 in healthy children in the U.S. and Canada and we thank NIAID [National Institute of Infectious Diseases] and BARDA [Biomedical Advanced Research and Development Authority] for their collaboration,” said Stephane Bancel, CEO of Moderna said. “It is humbling to know that 17.8 million adults in the U.S. have received the Moderna COVID-19 vaccine to date. We are encouraged by the primary analysis of the Phase 3 COVE study of mRNA-1273 in adults ages 18 and above and this pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.”

Children in the study are to be given two doses, 28 days apart. In the study’s first part, children ages two years to younger than 12 may get one of two dose levels, 50 or 100 micrograms and in addition, children six months to less than two years may receive one of three dose levels 25, 50 or 100 micrograms. In the second part, a short-term analysis will take place to determine which dose will be used.

The study participants will be monitored for a year after inoculation for signs of side effects and antibodies.

Presently, none of the three vaccines authorized by the Food and Drug Administration for emergency use — Pfizer/BioNTech, Moderna and Johnson & Johnson — are approved for anyone younger than 16.

Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

My News Matters to me - Washington Informer Donations

Be a Part of The Washington Informer Legacy

A donation of your choice empowers our journalists to continue the work to better inform, educate and empower you through technology and resources that you use.

Click Here Today to Support Black Press and be a part of the Legacy!

Subscribe today for free and be the first to have news and information delivered directly to your inbox.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker